title: Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma.
abstract: Our objectives were to assess survival and predictors for survival among lymphoma patients whose disease had progressed after autologous bone marrow (ABMT) or stem cell transplantation (ASCT). Patients transplanted at Hadassah University Hospital between October 1983 and February 1999 were included. We compared survival of patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) after relapse or progression. Predictors for survival were assessed in a multivariate model. Of 88 transplanted patients with HD and 152 with NHL, relapse/progression occurred in 27 (31%) and 75 (49%), respectively. Median survival postrelapse was 25 months for HD and 7.5 months for NHL (P=0.12). Seven relapsed patients with HD (26%) and 10 (13%) with NHL survived >4 years. In NHL, longer postrelapse survival was associated with indolent histologies (P=0.007). On multivariate analysis, factors associated with survival included attainment of remission postrelapse (for both diseases), use of prophylactic immunotherapy (for HD), LDH level and time from transplant to relapse (for NHL). The short-term prognosis for patients with disease progression postautologous transplant may be somewhat better for HD compared to NHL. Long-term survival is poor in both diseases. However, the survival times in the current study are twice as long as those previously reported. Treatment regimens with the potential for achieving remission may have an impact on survival.
authors.affiliation: Department of Social Medicine, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Paltiel
authors.forename: C
authors.initials: C
authors.lastname: Rubinstein
authors.forename: R
authors.initials: R
authors.lastname: Or
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.forename: L
authors.initials: L
authors.lastname: Gordon
authors.forename: L
authors.initials: L
authors.lastname: Deutsch
authors.forename: A
authors.initials: A
authors.lastname: Polliack
authors.forename: E
authors.initials: E
authors.lastname: Naparstek
mesh_terms: D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality*; D006689:Hodgkin Disease / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality* / Q000628:therapy*; D008297:Male; D011379:Prognosis; D012008:Recurrence; D016019:Survival Analysis; D014182:Transplantation, Autologous